KRAS and BRAF mutations in ovarian cancer
Author Information
Author(s): Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, Iida K, Fukumoto M, Miyazaki K
Primary Institution: Shimane University School of Medicine
Hypothesis
KRAS and BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
Conclusion
Ovarian cancer patients with KRAS or BRAF mutations may benefit from CI-1040 treatment.
Supporting Evidence
- Somatic mutations of either KRAS or BRAF were identified in 12 (20.6%) out of 58 ovarian carcinomas.
- Phosphorylated ERK1/2 expression was identified in 18 (38.2%) out of 45 ovarian carcinomas.
- KRAS/BRAF mutation was significantly correlated with FIGO stage I, II (P<0.001).
- CI-1040 treatment resulted in profound growth inhibition and apoptosis in cancer cells with KRAS or BRAF mutations.
Takeaway
This study found that certain mutations in ovarian cancer can help doctors choose better treatments for patients.
Methodology
The study examined KRAS and BRAF mutations in 58 ovarian carcinomas and tested the effects of the MEK inhibitor CI-1040 on cancer cell lines.
Limitations
The study did not find significant correlations between KRAS/BRAF mutations or p-ERK1/2 expression and overall survival.
Participant Demographics
Patients with ovarian carcinoma, including various histological types.
Statistical Information
P-Value
P<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website